Drug Enforcement Administration, 4974-4975 [2014-01782]
Download as PDF
4974
Federal Register / Vol. 79, No. 20 / Thursday, January 30, 2014 / Notices
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Dated: January 16, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Halo Pharmaceutical, Inc.
Manufacturer of Controlled
Substances; Notice of Registration;
Chattem Chemicals, Inc.
By Notice dated August 14, 2013, and
published in the Federal Register on
August 20, 2013, 78 FR 51210, Halo
Pharmaceutical, Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
By Notice dated August 14, 2013, and
published in the Federal Register on
August 20, 2013, 78 FR 51210, Chattem
Chemicals, Inc., 3801 St. Elmo Avenue,
Chattanooga, Tennessee 37409, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
[FR Doc. 2014–01707 Filed 1–29–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances;
Notice of Registration; Clinical
Supplies Management, Inc.
By Notice dated August 29, 2013, and
published in the Federal Register on
September 6, 2013, 78 FR 54913,
Clinical Supplies Management, Inc., 342
42nd Street South, Fargo, North Dakota
58103, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance with the sole
purpose of packaging, labeling, and
distributing to customers which are
qualified clinical sites, conducting FDAapproved clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Supplies Management, Inc., to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Clinical Supplies Management, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 14, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–01785 Filed 1–29–14; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
18:24 Jan 29, 2014
Jkt 232001
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone for sale to other
manufacturers and to manufacture other
controlled substances for distribution to
its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of Halo
Pharmaceutical, Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Halo Pharmaceutical, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
[FR Doc. 2014–01788 Filed 1–29–14; 8:45 am]
VerDate Mar<15>2010
PO 00000
Frm 00111
Fmt 4703
Schedule
Schedule
Sfmt 4703
Gamma
Hydroxybutyric
Acid
(2010).
4-Methoxyamphetamine (7411) ...
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers. Regarding (9640), the
company plans to manufacture another
controlled substance for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Chattem Chemicals, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Chattem Chemicals, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
E:\FR\FM\30JAN1.SGM
30JAN1
Federal Register / Vol. 79, No. 20 / Thursday, January 30, 2014 / Notices
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–01782 Filed 1–29–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Authority: 44 U.S.C. 3507(a)(1)(D).
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request;
Application for Approval of a
Representative’s Fee in Black Lung
Claim Proceedings Conducted by the
U.S. Department of Labor
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Office of
Workers’ Compensation Programs
sponsored information collection
request (ICR) revision titled,
‘‘Application for Approval of a
Representative’s Fee in Black Lung
Claim Proceedings Conducted by the
U.S. Department of Labor,’’ to the Office
of Management and Budget (OMB) for
review and approval for use in
accordance with the Paperwork
Reduction Act (PRA) of 1995 (44 U.S.C.
3501 et seq.).
DATES: Submit comments on or before
March 3, 2014.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://www.
reginfo.gov/public/do/PRAViewICR?ref_
nbr=201309-1240-002 (this link will
only become active on the day following
publication of this notice) or by
contacting Michel Smyth by telephone
at 202–693–4129, TTY 202–693–8064,
(these are not toll-free numbers) or
sending an email to DOL_PRA_
PUBLIC@dol.gov.
Submit comments about this request
by mail or courier to the Office of
Information and Regulatory Affairs,
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
18:24 Jan 29, 2014
Attn: OMB Desk Officer for DOL–
OWCP, Office of Management and
Budget, Room 10235, 725 17th Street
NW., Washington, DC 20503; by Fax:
202–395–6881 (this is not a toll-free
number); or by email: OIRA_
submission@omb.eop.gov. Commenters
are encouraged, but not required, to
send a courtesy copy of any comments
by mail or courier to the U.S.
Department of Labor—OASAM, Office
of the Chief Information Officer, Attn:
Departmental Information Compliance
Management Program, Room N1301,
200 Constitution Avenue NW.,
Washington, DC 20210; or by email:
DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–
4129, TTY 202–693–8064, (these are not
toll-free numbers) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
Jkt 232001
This ICR
seeks OMB approval under the PRA to
revise the Application for Approval of a
Representative’s Fee in Black Lung
Claim Proceedings Conducted by the
U.S. Department of Labor, Form CM–
972, to include information about how
a respondent with a disability may
contact the OWCP in order to receive
assistance in completing the form. There
is no change to the information
collected from the public.
Individuals filing with the OWCP,
Division of Coal Mine Workers’
Compensation for benefits under the
Black Lung Benefits Act may elect to be
represented or assisted by an attorney or
other representative. For those cases
that are approved, 30 U.S.C. 901 of the
Black Lung Benefits Act and 20 CFR
725.365–6 of the Black Lung
Regulations have established standards
for the information and documentation
that must be submitted to the program
for review so that the representative
may be paid for services rendered to the
claimant. Upon receipt of that evidence,
the adjudicating official is required by
regulation to evaluate the application
and, based on the supporting
information in the claim file, approve a
fee for services rendered. Form CM–972
provides a standardized format that
assists representatives participating in
the Black Lung Benefits Program to
submit the required information.
Form CM–972 is sent to and
completed by the authorized
representative of a black lung claimant
whose claim has been approved for
benefits. The completed form is then
returned to and evaluated by the district
director, administrative law judge, or
appropriate appellate tribunal before
whom the claimed services were
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00112
Fmt 4703
Sfmt 4703
4975
performed, and a fee amount is
determined.
This information collection is subject
to the PRA. A Federal agency generally
cannot conduct or sponsor a collection
of information, and the public is
generally not required to respond to an
information collection, unless it is
approved by the OMB under the PRA
and displays a currently valid OMB
Control Number. In addition,
notwithstanding any other provisions of
law, no person shall generally be subject
to penalty for failing to comply with a
collection of information that does not
display a valid Control Number. See 5
CFR 1320.5(a) and 1320.6. The DOL
obtains OMB approval for this
information collection under Control
Number 1240–0011. The current
approval is scheduled to expire on
January 31, 2014; however, the DOL
notes that existing information
collection requirements submitted to the
OMB receive a month-to-month
extension while they undergo review.
New requirements would only take
effect upon OMB approval. For
additional substantive information
about this ICR, see the related notice
published in the Federal Register on
September 11, 2013 (77 FR 55761).
Interested parties are encouraged to
send comments to the OMB, Office of
Information and Regulatory Affairs at
the address shown in the ADDRESSES
section within 30 days of publication of
this notice in the Federal Register. In
order to help ensure appropriate
consideration, comments should
mention OMB Control Number 1240–
0011. The OMB is particularly
interested in comments that:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Agency: DOL–OWCP.
Title of Collection: Application for
Approval of a Representative’s Fee in
E:\FR\FM\30JAN1.SGM
30JAN1
Agencies
[Federal Register Volume 79, Number 20 (Thursday, January 30, 2014)]
[Notices]
[Pages 4974-4975]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01782]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration;
Chattem Chemicals, Inc.
By Notice dated August 14, 2013, and published in the Federal
Register on August 20, 2013, 78 FR 51210, Chattem Chemicals, Inc., 3801
St. Elmo Avenue, Chattanooga, Tennessee 37409, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid (2010)........... I
4-Methoxyamphetamine (7411)................ I
Dihydromorphine (9145)..................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Lisdexamfetamine (1205).................... II
Methylphenidate (1724)..................... II
Pentobarbital (2270)....................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Tapentadol (9780).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution and sale to its customers. Regarding (9640),
the company plans to manufacture another controlled substance for sale
to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a), and determined that the registration
of Chattem Chemicals, Inc., to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Chattem Chemicals, Inc., to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical
[[Page 4975]]
security systems, verification of the company's compliance with state
and local laws, and a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-01782 Filed 1-29-14; 8:45 am]
BILLING CODE 4410-09-P